WASHINGTON, July 6, 2009 — With neuroscience on the threshold of unprecedented advances in understanding and treating Alzheimer’s disease, Parkinson’s disease, autism, and a range of other disorders of the brain and nervous system, the American Chemical Society (ACS) today announced plans to launch a new journal devoted to the molecular basis of neurological disease.
ACS Chemical Neuroscience will launch in January 2010 with Craig W. Lindsley, Ph.D., of Vanderbilt University School of Medicine, as Editor-in-Chief. The bimonthly journal will focus on the molecular aspects of neurological science in both health and disease.
Topics expected in the peer-reviewed, online-only publication include nerve activators and receptors; nerve growth and development; nerve imaging; pain and sensory processing; and the diagnosis and treatment of neurological diseases.
ACS Chemical Neuroscience targets a growing demand for publication of neuroscience research and represents an expansion of the ACS journal portfolio relating to biological chemistry. Utilizing ACS’ award-winning Web delivery platform, the journal will publish short features as well as peer-reviewed letters, articles, and reviews. The publication will include regular commentary features to discuss standards in the field as well as develop connections between technological advancements and applications. These features will serve to engage the diverse group of scientists working in the multidisciplinary neuroscience field.
Lindsley comes to the journal with both academic and industrial experience. “He brings a unique perspective of what it takes to do neuroscience research in both sectors,” said Evelyn Jabri, Ph.D., senior acquisitions editor for ACS Publications and project leader for the new journal.
Unlike some other neuroscience journals, ACS Chemical Neuroscience won’t levy charges for publication and color figures, Lindsley said. This and other author benefits, such as rapid review and publication process, will provide authors with a competitive edge in disseminating their work, he added.
Lindsley is currently Associate Professor of Pharmacology and Chemistry and Director of Medicinal Chemistry for the Vanderbilt Institute of Chemical Biology Program in Drug Discovery at Vanderbilt University School of Medicine in Nashville, Tenn.
He earned his B.S. in chemistry from California State University in 1992 and a Ph.D. in chemistry from the University of California, Santa Barbara, in 1996. After a postdoctoral fellowship at Harvard University, he conducted medicinal chemistry research at Parke-Davis Pharmaceuticals, Eli Lilly & Co., and Merck & Co. Lindsley joined the faculty of Vanderbilt in 2006. His research currently focuses on developing new treaments for schizophrenia, Parkinson’s disease, and other disorders.